Do β-adrenoceptor agonists induce homologous or heterologous desensitization in rat urinary bladder?

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 387, Issue 3, 2014, Pages 215-224

  Michel, Martin C ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

3 Adrenoceptor; Bladder; CL 316,243; Desensitization; Fenoterol; Mirabegron

Indexed keywords

5 [2 [[2 (3 CHLOROPHENYL) 2 HYDROXYETHYL]AMINO]PROPYL] 1,3 BENZODIOXOLE 2,2 DICARBOXYLIC ACID; CARBACHOL; FENOTEROL; FORSKOLIN; ISOPRENALINE; MIRABEGRON;

ANIMAL EXPERIMENT; ARTICLE; BLADDER; BLADDER CONTRACTION; BLADDER FUNCTION; CONTROLLED STUDY; DRUG EFFICACY; MALE; NONHUMAN; OVERACTIVE BLADDER; RAT; RECEPTOR DOWN REGULATION; SMOOTH MUSCLE TONE; URINARY BLADDER RELAXATION;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ADRENERGIC BETA-3 RECEPTOR AGONISTS; ADRENERGIC BETA-AGONISTS; ANIMALS; CARBACHOL; DIOXOLES; FENOTEROL; ISOPROTERENOL; MALE; MUSCARINIC AGONISTS; MUSCLE CONTRACTION; MUSCLE RELAXATION; POTASSIUM CHLORIDE; RATS; RATS, WISTAR; URINARY BLADDER; URINARY BLADDER, OVERACTIVE;

EID: 84896708299     PISSN: 00281298     EISSN: 14321912     Source Type: Journal    
DOI: 10.1007/s00210-013-0936-2     Document Type: Article

References (65)

1. Andersson K-E (2011) Antimuscarinic mechanisms and the overactive detrusor: an update. Eur Urol 59:377-386
2. Baker JG (2005) The selectivity of β-adrenoceptor antagonists at the human β1, β2 and β3 adrenoceptors. Br J Pharmacol 144:317-322
3. 3-adrenoceptors. Br J Pharmacol 160:1048-1061
4. 1- and β-adrenoceptor expression and function. Neurourol Urodyn 28:349-355
5. 2 KO animals. Naunyn-Schmiedeberg's Arch Pharmacol 385:1161-1173
6. 3-adrenoceptor gene expression in brown fat cells is transient and recovery is dependent upon a short-lived protein factor. J Biol Chem 271:33366-33375
7. Benner JS, Nichol MB, Rovner ES, Jumadilova Z, Alvir J, Huseein M, Fanning K, Trocio JN, Brubaker L (2010) Patient-reported reasons for discontinuing overactive bladder medication. BJU Int 105:1276-1282
8. Brubaker L, Fanning K, Goldberg EL, Benner JS, Trocio JN, Bavendam T, Jumadilova Z (2010) Predictors of discontinuing overactive bladder medications. BJU Int 105:1283-1290
9. 2-adrenergic receptors at the level of receptor phosphorylation and desensitization. Mol Pharmacol 56:813-823
10. 3-adrenergic receptor mutant. Endocrinol 137:2638-2641
11. Carpene C, Galitzky J, Collon P, Esclapez F, Dauzats M, Lafontan M (1993) Desensitization of beta-1 and beta-2, but not beta-3 adrenoceptor-mediated lipolytic responses of adipocytes after long-term norepinephrine infusion. J Pharmacol Exp Ther 265:237-247
12. sα and functional desensitization in a Chinese hamster ovary cell line expressing a β3-adrenoceptor refractory to down-regulation. Biochem J 303:973-978
13. 3-adrenoceptor agonist, in overactive bladder. Eur Urol 63:296-305
14. 3-adrenergic receptor. J Pharmacol Exp Ther 271:1253-1258
15. 1-adrenergic receptors are resistant to agonist-mediated regulation in human SK-N-MC neurotumor cells. Cell Signal 8:355-364
16. Dhein S, von Salisch S, Michel MC (2013) Cross-regulation between cardiac muscarinic acetylcholine receptors and β-adrenoceptors: lessons for use of knock-out mice. Naunyn-Schmiedeberg's Arch Pharmacol 386:1-3
17. Engelhardt S, Zieger W, Kassubek J, Michel MC, Lohse MJ, Brodde O-E (1997) Tocolytic therapy with fenoterol induces selective down-regulation of β-adrenergic receptors in human myometrium. J Clin Endocrinol Metab 82:1235-1242
18. Evans BA, Sato M, Sarwar M, Hutchinson DS, Summers RJ (2010) Ligand-directed signalling at β-adrenoceptors. Br J Pharmacol 159:1022-1038
19. 2- Adrenoceptor-mediated regulation of glucose uptake in skeletal muscle - ligand-idrected signalling or a reflection of system complexity? Naunyn-Schmiedeberg's Arch Pharmacol 386:757-760
20. Frazier EP, Mathy M-J, Peters SLM, Michel MC (2005) Does cyclic AMP mediate rat urinary bladder relaxation by isoproterenol? J Pharmacol Exp Ther 313:260-267
21. Frazier EP, Schneider T, Michel MC (2006) Effects of gender, age and hypertension on β-adrenergic receptor function in rat urinary bladder. Naunyn-Schmiedeberg's Arch Pharmacol 373:300-309
22. Frazier EP, Braverman AS, Peters SLM, Michel MC, Ruggieri MR Sr (2007) Does phospholipase C mediate muscarinic receptor-induced rat urinary bladder contraction? J Pharmacol Exp Ther 322:998-1002
23. 3- adrenoceptor agonist. Eur J Pharmacol 654:86-91
24. 3-adrenoceptor messenger ribonucleic acids in adipose tissues. Endocrinol 130:109-114
25. 3-adrenoceptor agonist mirabegron in cynomolgus monkeys. Naunyn-Schmiedeberg's Arch Pharmacol 386:1001-1008
26. 3-adrenoceptor agonist mirabegron in rats. Naunyn-Schmiedeberg's Arch Pharmacol 386:247-253
27. Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147:S80-S87
28. Hoffmann C, Leitz MR, Oberdorf-Maass S, Lohse MJ, Klotz K-N (2004) Comparative pharmacology of human β-adrenergic receptor subtypes - characterization of stably transfected receptors in CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 369:151-159
29. 3- Adrenoceptor regulation and relaxation responses in mouse ileum. Br J Pharmacol 129:1251-1259
30. 3- adrenoceptor agonists in clinical development for the treatment of overactive bladder syndrome. Naunyn-Schmiedeberg's Arch Pharmacol 386:177-183
31. Igawa Y, Schneider T, Yamazaki Y, Tatemichi S, Homma Y, Nishizawa O, Michel MC (2012) Functional investigation of β-adrenoceptors in human isolated detrusor focusing on the novel selective β3-adrenoceptor agonist KUC-7322. Naunyn-Schmiedeberg's Arch Pharmacol 385:759-767
32. Irwin DE, Milsom I, Hunskaar S, Reillly K, Kopp Z, Herschorn S, Coyne K, Kelleher C, Hampel C, Artibani W, Abrams P (2006) Population-based survey of urinary incontinence, overactive bladder, and other lower urinary tract symptoms in five countries: results of the EPIC study. Eur Urol 50:1306-1315
33. Kanie S, Otsuka A, Yoshikawa S, Morimoto T, Hareyama N, Okazaki S, Kobayashi R, Hasebe K, Nakao K, Hayashi R, Mochizuki H, Matsumoto R, Ozono S (2012) Pharmacological effect of TRK-380, a novel selective human β3-adrenoceptor agonist, on mammailian detrusor strips. Urology 79:744.e1-744.e7
34. 3- adrenoceptor agonists, in patients with overactive bladder: results from a randomised European-Australian phase 3 trial. Eur Urol 63:283-295
35. 2-adrenergic receptors. cAMP and the third intracellular loop of m1 muscarinic receptors confer heterologous regulation. J Biol Chem 268:7949-7957
36. Longhurst PA, Levendusky M (1999) Pharmacological characterization of β-adrenoceptors mediating relaxation of the rat urinary bladder in vitro. Br J Pharmacol 127:1744-1750
37. 3-adrenoceptor agonist: on the in vitro and in vivo studies. Naunyn-Schmiedeberg's Arch Pharmacol 385:845-852
38. 2 receptor knockout mice. J Pharmacol Exp Ther 305:106-113
39. Michel MC (2011) β-Adrenergic receptor subtypes in the urinary tract. In: Andersson K-E, Michel MC (eds) Urinary tract. Springer-Verlag, Berlin, pp 307-318
40. Michel MC, Barendrecht MM (2008) Physiological and pathological regulation of the autonomic control of urinary bladder contractility. Pharmacol Ther 117:297-312
41. Michel MC, Sand C (2009) Effect of pre-contraction on β-adrenoceptor-mediated relaxation of rat urinary bladder. World J Urol 27:711-715
42. 2- and β-adrenoceptors in the urinary bladder, urethra and prostate. Br J Pharmacol 147:S88-S119
43. Michel MC, Ochodnicky P, Homma Y, Igawa Y (2011) β-Adrenoceptor agonist effects in experimental models of bladder dysfunction. Pharmacol Ther 131:40-49
44. 3-adrenoceptors expressed in human embryonic kidney cells. Naunyn-Schmiedeberg's Arch Pharmacol 386:843-851
45. 3-adrenergic receptor is resistant to short term agonist-promoted desensitization. Mol Pharmacol 43:548-555
46. 3- adrenoceptor signalling. Br J Pharmacol 114:1045-1051
47. 2-adrenoceptor agonists can both stimulate and inhibit glucose uptake in mouse soleus muscle through ligand-directed signalling. Naunyn-Schmiedeberg's Arch Pharmacol 386:761-773
48. Nishimoto T, Latifpour J, Wheeler MA, Yoshida M, Weiss RM (1995) Age-dependent alterations in β-adrenergic responsiveness of rat detrusor smooth muscle. J Urol 153:1701-1705
49. Nitti V, Auerbach S, Martin N, Calhoun A, Lee M, Herschorn S (2013) Results of a randomized phase III trial of mirabegron in patients with overactive bladder. J Urol 189:1388-1395
50. Ochodnicky P, Uvelius B, Andersson K-E, Michel MC (2013) Autonomic nervous control of the urinary bladder. Acta Physiol 207:16-33
51. 3-adrenoceptor agonist solabegron for overactive bladder. Eur Urol 62:834-840
52. 3-adrenoceptor agonist, AJ-9677, on relaxation of the detrusor muscle: an in vitro study. Int J Urol 15:1072-1076
53. 3- adrenoceptor in human urinary bladder, a comparison with rat and mouse: implications for drug discovery. Eur J Pharmacol 690:202-206
54. Penn RB (2008) Embracing emerging paradigms of G protein-coupled receptor agonism and signaling to address airway smooth muscle pathobiology in asthma. Naunyn-Schmiedeberg's Arch Pharmacol 378:149-169
55. Rapp DE, Lyon MB, Bales GT, Cook SP (2005) A role for the P2X receptor in urinary tract physiology and in the pathophysiology of urinary dysfunction. Eur Urol 48:303-308
56. 3-adrenergic receptor mRNA and signal transduction by cold exposure in brown adipose tissue of young and senescent rats. Pflugers Arch 437:479-483
57. Schneider T, Fetscher C, Michel MC (2011) Human urinary bladder strip relaxation by the β-adrenoceptor agonist isoprenaline: methodological considerations and effects of gender and age. Front Pharmacol 2:11
58. Seamon KB, Daly JW (1986) Forskolin: its biological and chemical properties. Adv Cyclic Nucleotide Protein Phosphorylation Res 20:1-150
59. 3-adrenoceptor desensitization in HEK cells but not CHO cells. Naunyn-Schmiedeberg's Arch Pharmacol 386:841-842
60. 3-adrenoceptor agonist, on bladder function. J Pharmacol Exp Ther 321:642-647
61. Takeda H, Matsuzawa A, Igawa Y, Yamazaki Y, Kaidoh K, Akahane S, Kojima M, Miyata H, Akahane M, Nishizawa O (2003) Functional characterization of β-adrenoceptor subtypes in the canine and rat lower urinary tract. J Urol 170:654-658
62. Vaughan CP, Johnson TM II, Ala-Lipasti MA, Cartwright R, Tammela TLJ, Taari K, Auvinen A, Tikkinen KAO (2011) The prevalence of clinically meaningful overactive bladder: bother and quality of life results from the population-based FINNO study. Eur Urol 59:629-636
63. 3-adrenoceptors? Br J Pharmacol 156:127-134
64. Witte LPW, de Haas N, Mammen M, Stangeland EL, Steinfeld T, Aiyar J, Michel MC (2011) Muscarinic receptor subtypes and signalling involved in the attenuation of isoprenaline-induced rat urinary bladder relaxation. Naunyn-Schmiedeberg's Arch Pharmacol 384:555-563
65. 3-Adrenoceptors in urinary bladder. Neurourol Urodyn 26:752-756